Answers are grounded in this paper and cite their sources.
Pirtobrutinib is a highly selective, non-covalent BTK inhibitor that has expanded therapeutic options for CLL, particularly after failure of covalent BTK inhibitors. Unlike ibrutinib, acalabrutinib, and zanubrutinib, pirtobrutinib binds BTK reversibly and independently of C481, thereby retaining activity against C481-mutant clones. Emerging mechanistic data suggest that pirtobrutinib may also stabilize BTK in a closed, inactive conformation, limiting Y551 phosphorylation and potentially interfering with kinase-independent scaffold signaling. Clinically, pirtobrutinib has shown meaningful activity in relapsed/refractory CLL/SLL, including heavily pretreated and covalent BTK inhibitor-exposed populations, with durable responses and a generally manageable safety profile. In treatment-naïve CLL/SLL, pooled phase 3 data demonstrate high response rates, sustained progression-free survival, and low discontinuation due to adverse events. This review summarizes the pharmacologic rationale, clinical efficacy, safety profile, resistance patterns, and the evolving role of pirtobrutinib in contemporary CLL treatment sequencing and discusses how ongoing combination studies may further refine its future use.
No takes yet. Share an insight, caveat, or question.
Wysocka et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: